PCSK9 brings exorbitant price, and perhaps cost-control consensus

 - pharmaceuticals, money, economics
Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Specialty medications have been largely free from cost controls. But the introduction of injectable proprotein convertase subtilisin/kexin 9 (PCSK9) enzyme inhibitors to manage cholesterol—and the sticker shock the drug’s price will bring to consumers—might be the impetus for the healthcare system to develop consensus about the pricing of specialty medications, according to a post on the Health Affairs blog.